Save Product
Product Details
Source
Anti-Bevacizumab Antibody (AY9) is a Mouse monoclonal antibody produced from a hybridoma created by fusing SP2/0 myeloma and Mouse B-lymphocytes.
Clone
AY9
Species
Mouse
Isotype
Mouse IgG1/kappa
Antibody Type
Hybridoma Monoclonal
Reactivity
Human
Immunogen
Bevacizumab
Specificity
Recognizes Bevacizumab specifically.
Application
ApplicationRecommended UsageELISA20-10000 ng/mLPurity
95% as determined by SDS-PAGE.
Purification
Protein A purified / Protein G purified
Formulation
Lyophilized from a 0.22 μm-filtered solution in pH 7.5 containing Tris with Glycine, Arginine and NaCl, with trehalose as protectant.
Please contact us for customized product forms or formulations.
Reconstitution
Please refer to the Certificate of Analysis (CoA) for specific instructions.
For best performance, we strongly recommend following the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored in a lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- 4-8°C for 12 months in lyophilized state;
- -70°C for 12 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE
Anti-Bevacizumab Antibody (AY9) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
Bioactivity-ELISA
Anti-Bevacizumab Antibodies bridging ELISA for Anti-Drug Antibody (ADA) assay development. Immobilized bevacizumab at 1 µg/mL, add increasing concentrations of Anti-Bevacizumab Antibody (AY9) (Cat. No. BEB-Y9, 10% human serum) and then add biotinylated bevacizumab at 5 µg/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 9 ng/mL (QC tested).
Protocol
Demonstration of the specificity of Anti-Bevacizumab Antibody (AY9) (Cat. No. BEB-Y9) to the bevacizumab.
Protocol
Measured by its neutrlizing ability in a functional ELISA. Immobilized bevacizumab at 2 μg/mL (100 μL/well) can bind pre-mixed Anti-Bevacizumab Antibody (AY9) (Cat. No. BEB-Y9) and Biotinylated Human VEGF165, His,Avitag (Cat. No. VE5-H82Q0) with a inhibition rate of 62%.
Protocol
Bioactivity-MSD
Anti-Bevacizumab Antibodies bridging MSD for Anti-Drug Antibody (ADA) assay development. Added the mix solution (biotinylated Bevacizumab at 5 µg/mL, SULFO-Bevacizumab at 5 µg/mL and increasing concentrations of Anti-Bevacizumab Antibody (AY9) (Cat. No. BEB-Y9, 100% human serum). Detection was performed using MSD Assay with a sensitivity of 0.97 ng/mL.
Bioactivity-SPR
Anti-Bevacizumab Antibody (AY9) (mouse IgG1, Cat. No. BEB-Y9) captured on CM5 chip via anti-mouse antibodies surface, can bind human bevacizumab with an affinity constant of 1.92 nM.
Protocol
Customer Reviews Writing Reviews
Contact Us
Drug Candidate Licensing
